临床研究

H型高血压患者血尿酸水平与非酒精性脂肪性肝病的关系

  • 张瑶 ,
  • 霍迎新 ,
  • 赵伟 ,
  • 唐荣杰 ,
  • 廉秋芳
展开
  • 延安大学咸阳医院心血管内科 (陕西咸阳 712000);延安大学医学院 (陕西 延安 716000 )

收稿日期: 2023-11-23

  网络出版日期: 2024-09-30

基金资助

国家自然科学基金项目(82160090);陕西省重点研发计划项目(2023-YBSF-636);陕西省卫生健康科研基金项目(2021C003)

The relationship between blood uric acid levels and non⁃alcoholic fatty liver disease in patients with type H hypertension

  • Yao ZHANG ,
  • Yingxin HUO ,
  • Wei ZHAO ,
  • Rongjie TANG ,
  • Qiufang. LIAN
Expand
  • Department of Cardiology,Xianyang Hospital,Yan′an University,Xianyang 712000,China; Medical School,Yan′an University,Yan′an 716000,China

Received date: 2023-11-23

  Online published: 2024-09-30

摘要

目的 探讨H型高血压患者血尿酸(serum uric acid,SUA)水平与非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的关系。 方法 回顾性研究,收集2022—2023年在延安大学咸阳医院心血管内科住院的H型高血压患者共284例,根据是否患有NAFLD,分为合并NAFLD组88例和正常组196例。比较两组患者一般资料及实验室指标,采用多因素logistic回归分析H型高血压患者发生NAFLD的影响因素,进一步绘制ROC曲线观察SUA预测NAFLD的作用,并根据约登指数最大值选取最佳截断值。 结果 合并NAFLD组患者BMI、收缩压(systolic blood pressure, SBP)、舒张压(diastolic blood pressure,DBP)、总胆固醇(total cholesterol,TC)、甘油三酯(triglycerides,TG)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C)、SUA、γ-谷氨酰转肽酶(γ- Glutamyl transpeptidase,γ-GT)及谷丙转氨酶(alanine aminotransferase, ALT)水平均高于正常组,而年龄、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)低于正常组(P < 0.05)。多因素logistic回归分析结果显示,BMI(OR= 1.173,95%CI:1.066 ~ 1.291)、UA(OR= 1.005,95%CI:1.001 ~ 1.010)、TG(OR= 1.929,95%CI:1.042 ~ 3.574)水平升高是H型高血压患者发生NAFLD的危险因素(P < 0.05)。ROC曲线示SUA、TG、BMI及三者联合的曲线下面积(AUC)分别为0.709、0.707、0.750、0.796。 结论 发生NAFLD的H型高血压患者BMI及SUA、TG水平均较无脂肪肝组患者高,SUA水平升高是H型高血压患者发生NAFLD的危险因素,且SUA水平超过337 μmol/L对预测NAFLD有重要价值。

本文引用格式

张瑶 , 霍迎新 , 赵伟 , 唐荣杰 , 廉秋芳 . H型高血压患者血尿酸水平与非酒精性脂肪性肝病的关系[J]. 实用医学杂志, 2024 , 40(18) : 2561 -2565 . DOI: 10.3969/j.issn.1006-5725.2024.18.009

Abstract

Objective To explore the relationship between blood uric acid levels and non-alcoholic fatty liver disease in patients with type H hypertension. Methods The clinical data of 284 patients with type H hypertension admitted to the Cardiovascular Department, Xianyang Hospital, Yan'an University in 2022 were collected and retrospectively reviewed. The patients were divided into NAFLD group (n = 88)and normal group (n = 196) according to whether they had NAFLD. The general information and laboratory indicators were compared between the two groups. Multivariate logistic regression analysis was conducted to explore the influencing factors of NAFLD in H-type hypertension patients. The draw ROC curves were plotted to observe the role of SUA in predicting NAFLD and select the optimal cutoff value based on the maximum Youden index. Results The NAFLD group demonstrated higher levels in body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein cholesterol, SUA, γ-Glutamyl transpeptidase and alanine aminotransferase compared to the normal group, but significantly lower levels at age and high-density lipoprotein cholesterol(P < 0.05). The multivariate logistic regression analysis showed that elevated levels of BMI(OR= 1.173,95%CI:1.066 ~ 1.291), SUA(OR= 1.005,95%CI:1.001 ~ 1.010), and TG(OR= 1.929,95%CI:1.042 ~ 3.574)were risk factors for NAFLD in patients with type H hypertension (P < 0.05). The ROC curves showed that the area under the curve (AUC) of SUA, TG, BMI, and their combination were 0.709, 0.707, 0.750, and 0.796, respectively. Conclusion type H hypertensive NAFLD patients have high levels of BMI, SUA, TG compared to non-NAFLD patients. Elevated SUA is a risk factor for type H hypertensive NAFLD patients, with SUA > 337 μmol/L as a significant value for predicting NAFLD.

参考文献

1 杜诗虹,洪秀琴,杨一 等. 睡眠时间对女性人群H型高血压患病率的影响研究[J]. 中国全科医学, 2023,26(1):58-63.
2 COSTA D S, GUAHNON M P, SEGANFREDO F B, et al. Vitamin B12 and homocysteine levels in patients with nafld: A systematic review and metanalysis[J]. Arq Gastroenterol, 2021, 58(2):234-239. doi:10.1590/s0004-2803.202100000-42
3 ZHOU J, ZHOU F, WANG W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020,71(5):1851-1864. doi:10.1002/hep.31150
4 SAITO Y, TANAKA A, NODE K, Kobayashi Y. Uric acid and cardiovascular disease: A clinical review[J]. J Cardiol, 2021,78(1):51-57. doi:10.1016/j.jjcc.2020.12.013
5 ZHANG Y, SHI R, YU L,et al. Establishment of a risk prediction model for non-alcoholic fatty liver disease in type 2 diabetes[J]. Diabetes Ther, 2020,11(9):2057-2073. doi:10.1007/s13300-020-00893-z
6 HWANG I C, SUH S Y, SUH A R,et al. The relationship between normal serum uric acid and nonalcoholic fatty liver disease[J]. J Korean Med Sci, 2011,26(3):386-3891. doi:10.3346/jkms.2011.26.3.386
7 WANG J, ZHOU J, SHAO Z, et al. Association between serum uric acid and homocysteine levels among adults in the United States: A cross-sectional study[J]. BMC Cardiovasc Disord, 2023,23(1):599. doi:10.1186/s12872-023-03586-0
8 《中国高血压防治指南》修订委员会. 中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
9 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957. doi:10.3969/j.issn.1001-5256.2018.05.007
10 DUELL P B, WELTY F K, MILLER M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association[J]. Arterioscler Thromb Vasc Biol, 2022,42(6):e168-e185.
11 YOUNOSSI Z M. Non-alcoholic fatty liver disease-A global public health perspective[J]. J Hepatol, 2019,70(3):531-544.
12 CHEN P, YANG Z, GUO L,et al. Effects of homocysteine on nonalcoholic fatty liver related disease: A mendelian randomization study[J]. Front Mol Biosci, 2022,9:1083855. doi:10.3389/fmolb.2022.1083855
13 RONG L, ZOU J, RAN W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD) [J]. Front Endocrinol (Lausanne), 2023,13:1087260.
14 YU H, ZHAO L, LIU L, et al. Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients[J]. Medicine (Baltimore), 2021,100(33):e26946. doi:10.1097/md.0000000000026946
15 ZHENG X, GONG L, LUO R, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J]. Lipids Health Dis, 2017,16(1):202. doi:10.1186/s12944-017-0531-5
16 WEI F, LI J, CHEN C, et al. Higher serum uric acid level predicts non-alcoholic fatty liver disease: A 4-year prospective cohort study[J]. Front Endocrinol (Lausanne), 2020,11:179.
17 TANG Y, XU Y, LIU P, et al. No Evidence for a causal link between serum uric acid and nonalcoholic fatty liver disease from the Dongfeng-Tongji cohort study[J]. Oxid Med Cell Longev, 2022,2022:6687626.
18 郭进露,白涛,刘诗,等. 血尿酸与非酒精性脂肪肝相关性meta分析[J]. 临床消化病杂志,2021, 33(2):110-116.
19 PASCHOS P, ATHYROS V G, TSIMPERIDIS A,et al. Can serum uric acid lowering therapy contribute to the prevention or treatment of nonalcoholic fatty liver disease?[J]. Curr Vasc Pharmacol, 2018, 16(3):269-275.
20 陈诚. 同型半胱氨酸和非酒精性脂肪肝的相关性研究[D]. 广州:广州医科大学,2022.
21 胡新会,王桂君. 叶酸、维生素B12对非酒精性脂肪肝伴高同型半胱氨酸患者的疗效观察[J]. 锦州医科大学学报,2020,41(1):27-30,33.
22 FU L, WANG Y, HU Y Q. Association between homocysteine and nonalcoholic fatty liver disease: Mendelian randomisation study[J]. Eur J Clin Invest, 2023,53(3):e13895. doi:10.1111/eci.13895
23 WANG W, WANG Q, YANG N. Serum uric acid concentration is associated with hyperhomocysteinemia in hypertensive Chinese adults[J]. Blood Press Monit, 2022,27(3):147-151. doi:10.1097/mbp.0000000000000581
24 LOMBARDI R, PISANO G, FARGION S. Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD[J]. Int J Mol Sci, 2016,17(4):548. doi:10.3390/ijms17040548
25 JENSEN T, ABDELMALEK M F, SULLIVAN S, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease[J]. J Hepatol, 2018,68(5):1063-1075. doi:10.1016/j.jhep.2018.01.019
26 CHEN S, CHEN D, YANG H, et al. Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis[J]. BMC Gastroenterol, 2020,20(1):39. doi:10.1186/s12876-020-01189-z
27 WAN X, XU C, LIN Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism[J]. J Hepatol, 2016, 64(4):925-932. doi:10.1016/j.jhep.2015.11.022
28 SHARAF EL DIN U A A, SALEM M M, ABDULAZIM D O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review[J]. J Adv Res, 2017,8(5):537-548. doi:10.1016/j.jare.2016.11.004
29 TONG C, LI Q, KONG L, NI X, et al. Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence[J]. J Endocrinol Invest, 2022,45(12):2233-2245. doi:10.1007/s40618-022-01848-w
30 WANG S, SHENG F, ZOU L,et al. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism[J]. J Adv Res, 2021,34:109-122. doi:10.1016/j.jare.2021.06.001
31 ZEYBEL M, ALTAY O, ARIF M, et al. Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients[J]. Mol Syst Biol, 2021,17(10):e10459. doi:10.15252/msb.202110459
文章导航

/